The most common grade 3/4 adverse events with ADI-PEG 20 were neutropenia (11%), fatigue (7%), anaphylactoid/anaphylaxis (7%), rash (2%), and serum sickness (2%).
ADAM was funded by Cancer Research UK. Polaris Pharmaceuticals provided the study drug. Dr. Szlosarek disclosed ties with Roche and BMS. A coauthor reported ties with Polaris Group.